Comparing demographics, clinical presentation, treatments and outcome between systemic lupus erythematosus patients treated in a public and private health system in Santa Fe, Argentina

Reumatol Clin. 2014 Sep-Oct;10(5):294-8. doi: 10.1016/j.reuma.2013.12.009. Epub 2014 Jun 27.

Abstract

The study includes 159 SLE patients seen between 1987 and 2011, of whom 116 were treated in the public health system and 43 in private practice. In the comparison between both groups, it was shown that patients in the public health system were younger at first consultation and at the onset of SLE, and that the mean duration of their disease prior to nephropathy was statistically significantly shorter. They also presented with more SLE activity (measured by Systemic Lupus Erythematosus Activity Index) such as fever, lower levels of C4, and elevated erythrocyte sedimentation rate. Although cyclophosphamide was administered more frequently to patients in the public health system group, there were no statistically significant differences in renal histological findings. A second renal biopsy was performed on 20 patients due to the presence of persistent proteinuria, peripheral edema, urinary casts, or because of previous defective renal specimens. The overall 10-year survival of the patients in the public health system was 78% compared to a survival rate of 91% for the patients in private practices. When survival was evaluated at 15 years, however, no differences were found (log rank test: 0.65). Patients from both public and private groups attended medical specialist practices and received early diagnoses and close follow-ups.

Keywords: Desenlace en lupus eritematoso sistémico; Health systems; Lupus eritematoso sistémico; Sistemas de salud; Supervivencia en lupus eritematoso sistémico; Systemic lupus erythematosus; Systemic lupus erythematosus outcomes; Systemic lupus erythematosus survival.

Publication types

  • Comparative Study
  • Observational Study

MeSH terms

  • Adult
  • Argentina
  • Cross-Sectional Studies
  • Delivery of Health Care
  • Demography
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / diagnosis*
  • Lupus Erythematosus, Systemic / mortality
  • Lupus Erythematosus, Systemic / therapy*
  • Male
  • Private Sector
  • Public Sector
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome